Singular Genomics complies with Nasdaq's minimum bid price requirement, positive.

From GlobeNewswire: 2024-07-15 16:05:00

Singular Genomics Systems, Inc. (Nasdaq: OMIC) has regained compliance with Nasdaq’s minimum bid price requirement after the closing bid price per share was $1.00 or greater for 11 consecutive days from June 26, 2024, to July 11, 2024. The company leverages next-generation sequencing and multiomics technologies to empower researchers and clinicians. Singular Genomics develops the G4® Sequencing Platform, a fast and accurate genomic sequencer, and is working on the G4X™ Spatial Sequencer for spatial applications in tissue. The company’s mission is to advance science and medicine through innovative technologies.



Read more at GlobeNewswire: Singular Genomics Regains Compliance with Nasdaq Minimum